Genomic testing has transformed treatment decisions for hormone receptor-positive, HER2-negative (HR+/HER2−) early breast cancer; however, it remains inaccessible to many patients worldwide due to high costs and logistical barriers. Here, ERBB2 is linked to breast carcinoma.